Shares of Dermira Inc (NASDAQ:DERM) have received a consensus recommendation of “Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $16.15.
DERM has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Dermira in a research note on Friday, October 18th. Zacks Investment Research raised Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price target for the company in a research note on Wednesday, October 9th. BidaskClub raised Dermira from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 19th. Finally, Leerink Swann reduced their price target on Dermira from $23.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th.
In related news, Director Matthew K. Fust sold 6,000 shares of Dermira stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total value of $52,620.00. Following the completion of the sale, the director now owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.40% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Hong Kong Ltd increased its holdings in shares of Dermira by 124.2% during the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,310 shares during the last quarter. Bank of Montreal Can lifted its holdings in Dermira by 621.8% in the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 3,905 shares during the last quarter. Advisor Group Inc. lifted its holdings in Dermira by 41.7% in the 2nd quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 2,527 shares during the last quarter. Atria Investments LLC bought a new stake in Dermira during the second quarter valued at about $85,000. Finally, Virtu Financial LLC acquired a new stake in shares of Dermira in the third quarter valued at about $85,000. 94.75% of the stock is currently owned by institutional investors and hedge funds.
Dermira stock opened at $7.88 on Monday. The company’s fifty day simple moving average is $7.59 and its 200-day simple moving average is $8.24. The company has a quick ratio of 6.63, a current ratio of 7.03 and a debt-to-equity ratio of 25.08. Dermira has a 12 month low of $5.25 and a 12 month high of $15.48. The stock has a market cap of $429.63 million, a P/E ratio of -1.50 and a beta of 1.37.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.40) by $0.34. The business had revenue of $11.53 million during the quarter, compared to analyst estimates of $11.07 million. Dermira had a negative return on equity of 583.07% and a negative net margin of 256.08%. On average, equities research analysts expect that Dermira will post -4.21 earnings per share for the current fiscal year.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Story: Strangles
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.